our Premium Content: News alerts, weekly reports and conference planners

GENE:

ELAC2 (ElaC Ribonuclease Z 2)

News alerts, weekly reports and conference planners

6ms

Multi-omic insights into mitochondrial dysfunction and prostatic disease: evidence from transcriptomics, proteomics, and methylomics. (PubMed, Front Genet)

We also explored the mediating pathways of mitochondrial genes (within the 3-tiers evidence) on prostatic diseases, and identified 8, 4, and 13 metabolites mediating the interaction between mitochondrial genes and BPH, prostatitis, and PCa, respectively, without the involvement of immune characters. These findings highlight the roles of mitochondrial dysfunction-related genes in prostatic diseases and identify key genes and pathways for potential therapeutic targets.

6 months ago

Journal

ACAT1 (Acetyl-CoA Acetyltransferase 1) • ELAC2 (ElaC Ribonuclease Z 2)

9ms

Integrating molecular diagnostics for early prostate cancer detection. (PubMed, Oncoscience)

Integrating genetic, molecular, or imaging readouts with additional imaging modalities, such as mpMRI offers opportunities for improved diagnostic accuracy and conceivable tailored treatment approaches. Larger multiethnic studies are needed to confirm these findings and define a genetic screening protocol for PCa.

9 months ago

Journal • BRCA Biomarker

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ELAC2 (ElaC Ribonuclease Z 2) • HOXB13 (Homeobox B13)

1year

Targeting mitochondrial RNAs enhances the efficacy of the DNA-demethylating agents. (PubMed, Sci Rep)

Hypomethylating agents (HMAs) such as azacytidine and decitabine are FDA-approved chemotherapy drugs for hematologic malignancy. Moreover, we show that a small molecular inhibitor of POLRMT compromises the metabolic activity and synergistically enhances the cytotoxicity of HMAs. Our study unveils the insensitivity to HMAs through the elevation of mtRNAs and suggests mtRNA regulatory factors as potential synergistic targets to improve the therapeutic benefit of HMAs.

1 year ago

Journal

ELAC2 (ElaC Ribonuclease Z 2)

azacitidine • decitabine

over1year

Structural insights into human ELAC2 as a tRNA 3' processing enzyme. (PubMed, Nucleic Acids Res)

We further used biochemical assays to analyse the structural effects of disease-related mutations of human ELAC2. Collectively, our data provide a comprehensive structural basis for how ELAC2 recruits pre-tRNA via its flexible arm domain and guides the 3' trailer of pre-tRNA into the active centre for cleavage by its C-terminal helix.

over 1 year ago

Journal

ELAC2 (ElaC Ribonuclease Z 2)

over1year

Structural basis of NEAT1 lncRNA maturation and menRNA instability. (PubMed, Nat Struct Mol Biol)

Here we report the crystal structure of human menRNA, which partially mimics tRNAs to drive RNase P and ELAC2 processing. Biophysical analyses uncover an RNA-centric, riboswitch-like mechanism whereby the nascent CCA reshapes the RNA folding landscape and propels a spontaneous conformational isomerization that directs repeat CCA addition, marking the menRNA and defective tRNAs for degradation.

over 1 year ago

Journal

NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • ELAC2 (ElaC Ribonuclease Z 2)

over1year

Structural basis of MALAT1 RNA maturation and mascRNA biogenesis. (PubMed, Nat Struct Mol Biol)

Rotation and repositioning of the D-stem and anticodon regions preclude mascRNA from aminoacylation, avoiding interference with translation. Therefore, a class of metazoan lncRNA loci uses a previously unrecognized, unusually streamlined quasi-tRNA architecture to recruit select tRNA-processing enzymes while excluding others to drive bespoke RNA biogenesis, processing and maturation.

over 1 year ago

Journal

MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • ELAC2 (ElaC Ribonuclease Z 2)

over2years

Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ. (PubMed, Prostate)

Higher frequencies of risk alleles were confirmed in the SNPs, KLK3 rs2735839_A, ELAC2 rs4792311_A, and TMPRSS2 rs12329760_T in patients with Pca. Rs2735839_A was associated with risk of Pca and rs4792311_A with severity and Gleason score of 7(4 + 3) or greater. There is a need for careful observation of rs2735839 and rs4792311 in association with the prostatic biopsy due to the increased risk of Pca.

over 2 years ago

Journal

CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ERG (ETS Transcription Factor ERG) • ELAC2 (ElaC Ribonuclease Z 2) • KLK3 (Kallikrein-related peptidase 3)

over2years

Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER) (IASLC-WCLC 2023)

Germline testing in this prospective cohort of driver positive NSCLC was able to identify PGV in 19.5% of patients which is slightly higher than what has been reported in general LC population (8-11%).

over 2 years ago

Clinical • BRCA Biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • TSC1 (TSC complex subunit 1) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCL (FA Complementation Group L) • MUTYH (MutY homolog) • FANCM (FA Complementation Group M) • ELAC2 (ElaC Ribonuclease Z 2) • RECQL4( RecQ Like Helicase 4) • KIF1B (Kinesin Family Member 1B)

TP53 mutation • BRAF V600E • EGFR mutation • BRAF V600 • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • BRIP1 mutation • TSC1 mutation • NBN mutation • ALK-ROS1 fusion

over2years

Microcystin-leucine-arginine promotes the development of gallbladder carcinoma via regulating ELAC2. (PubMed, Biochem Biophys Res Commun)

Furthermore, ELAC2 was identified as a critical mRNA involved in GBC progression through RNA sequencing. Collectively, our study suggests that MC-LR might be involved in the development of GBC by modulating the expression of ELAC2.

over 2 years ago

Journal

ELAC2 (ElaC Ribonuclease Z 2)

over2years

ELAC2 is a functional prostate cancer risk allele. (PubMed, Trends Mol Med)

Stentenbach and colleagues have unveiled a functional role of a human germline mutation found in the ribonuclease (RNase) Z enzyme, ELAC2, in prostate cancer. Here, we discuss the importance of these findings in enhancing our understanding of how risk variants enable prostate cancer progression and the post-transcriptional mechanisms underlying oncogenesis.

over 2 years ago

Journal

ELAC2 (ElaC Ribonuclease Z 2)

over2years

Multi-omic profiling reveals an RNA processing rheostat that predisposes to prostate cancer. (PubMed, EMBO Mol Med)

Multiomic profiling revealed defects in energy metabolism that activated proinflammatory and tumorigenic pathways as a consequence of impaired noncoding RNA processing and reduced protein synthesis. Our physiologically relevant models show that the ELAC2 variant is a predisposing factor for prostate cancer and identify changes that underlie the pathogenesis of this cancer.

over 2 years ago

Journal

ELAC2 (ElaC Ribonuclease Z 2)

ELAC2 mutation

3years

Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso. (PubMed, Prostate Cancer)

However, we found that 100% of homozygous carriers of the T650 mutation have an A1621 mutation (p ≤ 0.001). Ser217Leu and Ala541Thr polymorphisms of ELAC2, considered alone or in combination, are not associated with prostate cancer risk.

3 years ago

Journal

ELAC2 (ElaC Ribonuclease Z 2)